ClinicalTrials.gg
CompletedNCT02652364Updated Mar 19, 2020

Strong Ion Gap as Prognostic Indicator for Adult Patients Admitted With Shock to the Intensive Care Units

An observational study in Shock, sponsored by Singapore General Hospital. Completed at 1 site in Singapore. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-03-19.

Sponsored by Singapore General Hospital · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
112
Ages
21 Years to 99 Years
Sex
All
01

Study summary

This study evaluates if strong ion gap on admission or 24 hours after admission to critical care unit can predict 28 day outcome in patients admitted with shock due to any cause

Read the detailed description

Metabolic acidosis is frequently found in patients with shock. Traditional methods of evaluating acid-base status can underestimate and even miss complex acid-base disorders particularly in the setting of hypoalbuminemia, hypo/hypernatraemia and hypo/hyperchloraemia .An alternative approach to acid-base balance, based on chemical and physical principles, and was proposed by Peter Stewart more than 30 years ago. Later in 1992 Figge and Fencl modified the strong ion difference, which corresponds with the net charge balance of all strong ions present in a given solution (the ''Fencl-Stewart'' approach). The strong ion gap (SIG) which corresponds with the difference between the apparent strong ion difference and the effective strong ion difference was proposed by Kellum. Compared to the Fencl- Stewart approach SIG has more accuracy and bedside practicality.

As the SIG is calculated from all known charged components of blood, it is considered the gold standard for the quantification of unmeasured anions. In contrast, the traditional anion gap calculation only factors in sodium, potassium, chloride and bicarbonate. In healthy humans, the SIG equals zero. In critically ill patients, a high SIG, defined as >2mEq/L, indicates the accumulation of unmeasured anions in blood as a cause of acidosis. The unmeasured anions include lactate, ketoacids, uraemic acids and toxins like ethylene glycol and methanol. Studies found that a higher SIG on admission to intensive care unit is associated with poorer outcomes, and has a role in prediction of outcome in septic patients. However this finding is not consistent.

In addition it was found that there is a significant difference in the threshold for SIG value associated with higher mortality. The abnormal SIG value in American studies are described around 5 mEq/l . However studies from Europe and Australia reported higher values in the range of 8-13 mEq/l. It is speculated that this difference is due to exogenous sources of unmeasured ions from gelatin based intravenous fluids used for resuscitation. Interestingly studies using gelatine- based fluids also failed to show a correlation between SIG and mortality. SIG values have not been published in critically ill Asian adult patients admitted to the Intensive Care Units (ICU) as yet. We aim to find the SIG for these patients in the hope that it will be useful for predicting outcome. Our hypothesis is that SIG is an independent predictor of outcomes in adult patient with shock.

We propose to conduct this prospective observational study in the surgical and medical ICUs of 2 hospitals in Singapore. (Singapore General Hospital and Changi General Hospital) We aim to enrol 112 of you admitted to the ICU with shock of any etiology. Shock is defined as persistence of arterial hypotension despite adequate volume resuscitation. Hypotension is defined as systolic pressure \<90mmHg, Mean arterial pressure (MAP)\<70 mmHg or drop in SBP >40 mmHg from baseline. 30ml/kg of fluid is considered as the threshold for adequate volume resuscitation.

The methodology of this observational study was approved by Sing health Institutional review Board, Singapore. We will include you if you have persistent hypotension despite adequate fluid resuscitation as defined above or if you require vasopressors or inotropes to maintain MAP above 65mmHg on admission.

We will exclude the conditions with acid base disturbance which are not amenable to using standard supportive care such as pre-existing chronic kidney disease stage 3 and above ( defined as estimated GFR\<60 ml/min/1.73m2 ) and chronic liver failure.

Blood samples will be taken from indwelling intra-arterial catheters on admission and 24 hours after admission. Blood samples will be analyzed in the respective hospital laboratory for Arterial Blood Gas(ABG) analysis, electrolytes albumin and lactate levels in order to calculate the SIG.

All of you included in the study will be managed by the same group of critical care physician in accordance with pre-existing protocols in both ICUs to ensure that there will not be any major discrepancies among patients in terms of organ support and therapy. Haemodynamic support will be applied to reverse the hypotension and to correct peripheral perfusion abnormalities after optimal resuscitation. IV noradrenaline is the vasopressor of first choice followed by vasopressin and adrenaline.

Data collection-

Fluid resuscitation before ICU admission, SOFA and APACHE II score 24 hours after the admission, requirement for vasopressors, mechanical ventilation renal replacement therapy(RRT) ,duration of ICU stay, number of ventilator days, duration of vasopressor support, number of vasopressors used and the duration of RRT, 28 day outcome will be collected.

Calculation of SIG-

SIG will be calculated according to the following formulae;

  1. SIG= SIDapp - SIDeff

    (SIDapp -Strong ion difference apparent; SIDeff - Strong ion difference effective)

  2. SIDapp = ( Na++K++Ca2++Mg2+) - (Cl-+Lactate-)

    ( all concentrations in mEq/l)

  3. SIDeff = 2.46 x 10-8 x Pco2/ 10-pH + [albumin] x ( 0.123xpH - 0.631) +[PO43-] x (0.309xpH -0.469)

(PCO2 is measured in mm Hg, albumin in g/L, and phosphate in mmol/L)

02

Conditions studied

  • Shock

Browse trials for

03

In context

Shock

921 studies on the registry are indexed under Shock; 172 are open to participants now.

This study's enrollment of 112 is above the median of 93 across 355 observational studies indexed under Shock.

Browse Shock studies →

Lead sponsor

Singapore General Hospital is the lead sponsor of 270 studies on the registry; 58 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with any form of shock on admission to ICU defined by those who require vasopressors or inotropes to maintain MAP > 65mmHg on admission

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with any form of shock on admission to ICU

Exclusion criteria

Exclusion Criteria:

  • CKD stage 3 and above (GFR> 60)
  • Chronic liver failure( Child's B grade and above)
  • Patients who were already recruited for this study
  • Patients expected to die within next 48 hrs upon admission
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
112 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. mortality

    Time frame: 28 days

Secondary outcomes

  1. Duration of ICU stay

    number of days patient spent in ICU

    Time frame: 28 days

07

Study locations

1 site
  • Singapore General Hospital
    Singapore, 169608, Singapore
08

References and documents

Publications

  • Mecher C, Rackow EC, Astiz ME, Weil MH. Unaccounted for anion in metabolic acidosis during severe sepsis in humans. Crit Care Med. 1991 May;19(5):705-11. doi: 10.1097/00003246-199105000-00018. PubMed 2026034 ↗
  • Figge J, Mydosh T, Fencl V. Serum proteins and acid-base equilibria: a follow-up. J Lab Clin Med. 1992 Nov;120(5):713-9. PubMed 1431499 ↗
  • Figge J, Jabor A, Kazda A, Fencl V. Anion gap and hypoalbuminemia. Crit Care Med. 1998 Nov;26(11):1807-10. doi: 10.1097/00003246-199811000-00019. PubMed 9824071 ↗
  • Stewart PA. Modern quantitative acid-base chemistry. Can J Physiol Pharmacol. 1983 Dec;61(12):1444-61. doi: 10.1139/y83-207. PubMed 6423247 ↗
  • Kellum JA, Kramer DJ, Pinsky MR. Strong ion gap: a methodology for exploring unexplained anions. J Crit Care. 1995 Jun;10(2):51-5. doi: 10.1016/0883-9441(95)90016-0. PubMed 7647842 ↗
  • Gunnerson KJ. Clinical review: the meaning of acid-base abnormalities in the intensive care unit part I - epidemiology. Crit Care. 2005 Oct 5;9(5):508-16. doi: 10.1186/cc3796. Epub 2005 Aug 10. PubMed 16277740 ↗
  • Kellum JA. Closing the gap on unmeasured anions. Crit Care. 2003 Jun;7(3):219-20. doi: 10.1186/cc2189. Epub 2003 May 8. PubMed 12793870 ↗
  • Rutherford EJ, Morris JA Jr, Reed GW, Hall KS. Base deficit stratifies mortality and determines therapy. J Trauma. 1992 Sep;33(3):417-23. doi: 10.1097/00005373-199209000-00014. PubMed 1404512 ↗
  • Smith I, Kumar P, Molloy S, Rhodes A, Newman PJ, Grounds RM, Bennett ED. Base excess and lactate as prognostic indicators for patients admitted to intensive care. Intensive Care Med. 2001 Jan;27(1):74-83. doi: 10.1007/s001340051352. PubMed 11280677 ↗
  • Balasubramanyan N, Havens PL, Hoffman GM. Unmeasured anions identified by the Fencl-Stewart method predict mortality better than base excess, anion gap, and lactate in patients in the pediatric intensive care unit. Crit Care Med. 1999 Aug;27(8):1577-81. doi: 10.1097/00003246-199908000-00030. PubMed 10470767 ↗
  • Kaplan LJ, Kellum JA. Initial pH, base deficit, lactate, anion gap, strong ion difference, and strong ion gap predict outcome from major vascular injury. Crit Care Med. 2004 May;32(5):1120-4. doi: 10.1097/01.ccm.0000125517.28517.74. PubMed 15190960 ↗
  • Funk GC, Doberer D, Sterz F, Richling N, Kneidinger N, Lindner G, Schneeweiss B, Eisenburger P. The strong ion gap and outcome after cardiac arrest in patients treated with therapeutic hypothermia: a retrospective study. Intensive Care Med. 2009 Feb;35(2):232-9. doi: 10.1007/s00134-008-1315-1. Epub 2008 Oct 14. PubMed 18853143 ↗
  • Noritomi DT, Soriano FG, Kellum JA, Cappi SB, Biselli PJ, Liborio AB, Park M. Metabolic acidosis in patients with severe sepsis and septic shock: a longitudinal quantitative study. Crit Care Med. 2009 Oct;37(10):2733-9. doi: 10.1097/ccm.0b013e3181a59165. PubMed 19885998 ↗
  • Cusack RJ, Rhodes A, Lochhead P, Jordan B, Perry S, Ball JA, Grounds RM, Bennett ED. The strong ion gap does not have prognostic value in critically ill patients in a mixed medical/surgical adult ICU. Intensive Care Med. 2002 Jul;28(7):864-9. doi: 10.1007/s00134-002-1318-2. Epub 2002 Jun 14. PubMed 12122523 ↗
  • Rocktaeschel J, Morimatsu H, Uchino S, Bellomo R. Unmeasured anions in critically ill patients: can they predict mortality? Crit Care Med. 2003 Aug;31(8):2131-6. doi: 10.1097/01.CCM.0000079819.27515.8E. PubMed 12973170 ↗
  • Hayhoe M, Bellomo R, Liu G, McNicol L, Buxton B. The aetiology and pathogenesis of cardiopulmonary bypass-associated metabolic acidosis using polygeline pump prime. Intensive Care Med. 1999 Jul;25(7):680-5. doi: 10.1007/s001340050930. PubMed 10470571 ↗
  • Gunnerson KJ, Srisawat N, Kellum JA. Is there a difference between strong ion gap in healthy volunteers and intensive care unit patients? J Crit Care. 2010 Sep;25(3):520-4. doi: 10.1016/j.jcrc.2009.11.001. Epub 2009 Nov 25. PubMed 19942401 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Oct 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2016
First posted
Jan 11, 2016
Start
Oct 2015
Primary completionActual
Oct 2017
CompletionActual
Oct 2017
Last update
Mar 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02652364
Responsible party
Sponsor
First posted
Jan 11, 2016
Start date
Oct 2015
Primary completion
Oct 2017
Completion
Oct 2017
Last update
Mar 19, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion